Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

317 Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-
Limón JM et al. Controlled clinical trial of IV cyclophosphamide versus IV
methylprednisolone in severe neurological manifestations in systemic lupus
erythematosus. Ann Rheum Dis 2005; 64: 620–625.
318 Gonzalez-Lopez L, Cardona-Munoz E, Celis A, García-de la Torre I, Orozco-Barocio G,
Salazar-Paramo M. Therapy with intermittent pulse cyclophosphamide for pulmonary
hypertension associated with systemic lupus erythematosus. Lupus 2004; 13: 105–112.
319 Petri M, Brodsky R a, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose
cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus
erythematosus: a prospective randomized trial. Arthritis Rheum 2010; 62: 1487–1493.
320 Hahn B, Kantor O, Osterland K. Azathioprine plus prednisone compared with prednisone
alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled
trial in 24 patients. Ann Intern Med 1975; 83: 597–605.
321 Griffiths B, Emery P, Ryan V, Isenberg D, Akil M, Thompson R et al. The BILAG multicentre
open randomized controlled trial comparing ciclosporin vs azathioprine in patients
with severe SLE. Rheumatology 2010; 49: 723–732.
322 Carneiro J, Sato E. Double blind, randomized, placebo controlled clinical trial of
methotrexate in systemic lupus erythematosus. J Rheumatol 1999; 26: 1275–1279.
323 Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroidsparing
effects of methotrexate in systemic lupus erythematosus: a double-blind,
randomized, placebo-controlled trial. Arthritis Rheum 2008; 59: 1796–1804.
324 Tam L, Li E, Wong C, Lam C, Szeto C. Double-blind, randomized, placebo-controlled
pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004; 13: 601–604.
325 Dammacco F, Alberighi O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E. Cyclosporine-
A plus steroids versus steroids alone in the 12-month treatment of systemic lupus
erythematosus. Int J Clin Exp Med 2000; 30: 67–73.
326 Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into
mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol
2012; 8: 522–33.
327 Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M a. Clinical efficacy and
side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann
Rheum Dis 2010; 69: 20–8.
328 Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez L a, Scherbarth HR et al.
Antimalarial treatment may have a time-dependent effect on lupus survival: data from a
multinational Latin American inception cohort. Arthritis Rheum 2010; 62: 855–862.
329 Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for
thrombosis and primary thrombosis prevention in patients with systemic lupus
erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–
36.
GUÍA DE PRÁCTICA CLÍNICA SOBRE LUPUS ERITEMATOSO SISTÉMICO 459